Caribou Biosciences (CRBU) Net Cash Flow (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Net Cash Flow data on file, last reported at -$319000.0 in Q1 2026.

• Quarterly Net Cash Flow fell 102.43% year-over-year to -$319000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$17.4 million (up 13.01% YoY) and the FY2025 annual result came in at -$3.9 million, up 88.7% from the prior year.
• Net Cash Flow fell to -$319000.0 in Q1 2026 per CRBU's latest filing, from $1.2 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $37.9 million in Q3 2023 and bottomed at -$92.8 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$5.9 million (2024), against an average of -$13.4 million.
• The widest annual swing landed in 2024, when Net Cash Flow sank 185.75%; it then soared 844.84% in 2025.
• Tracing CRBU's Net Cash Flow over 5 years: stood at -$23.7 million in 2022, then sank by 122.75% to -$52.9 million in 2023, then surged by 70.36% to -$15.7 million in 2024, then jumped by 107.71% to $1.2 million in 2025, then slumped by 126.41% to -$319000.0 in 2026.
• Per Business Quant, the three latest CRBU Net Cash Flow figures stand at -$319000.0 (Q1 2026), $1.2 million (Q4 2025), and -$14.1 million (Q3 2025).

Peer Comparison